Table 2

Relative risk of COPD exacerbations stratified by severity in patients randomised to fluticasone and placebo groups over one year.
	COPD exacerbations					Relative risk of COPD exacerbation for patients randomised to placebo or fluticasone (n = 260)
	Fluticasone (n = 128)		Placebo (n = 132)		Mean days of patient exposure	Exacerbation grouping	Incidence rate ratio	95% confidence interval		adjusted p-value

Exacerbations while in trial	Unreported	129	Unreported	116	235 in fluticasone, 179 in placebo	All	1.11	0.91	1.36	0.298
	Moderate	224	Moderate	276
	Severe	21	Severe	22		Moderate and severe only	1.25	0.96	1.58	0.067
	Total	373	Total	413

Exacerbations while on randomised treatment	Unreported	112	Unreported	99	371 in both groups	All	1.48	1.17	1.86	0.001
	Moderate	158	Moderate	182
	Severe	9	Severe	12		Moderate and severe only	1.63	1.23	2.17	0.001
	Total	279	Total	293

Choudhury et al. Respiratory Research 2007 8:93 doi:10.1186/1465-9921-8-93